A study to assess the bioequivalence of dapagliflozin/metformin XR fixed-dose combination tablets in healthy subjects

Trial Identifier: D1691C00008
Sponsor: AstraZeneca
NCTID:: NCT02637037
Start Date: December 2015
Primary Completion Date: April 2016
Study Completion Date: April 2016
Condition: Other; Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation

Trial Locations

Country Location
United States of America, MD Baltimore, MD, United States of America, 21225